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Crystal Engineering of Binary Compounds 
Containing Pharmaceutical Molecules 
 
Leslie Ann Morales 
 
ABSTRACT 
 
 
 
The synthesis or the interaction between two or more molecules is known as 
supramolecular chemistry.  The concept of supramolecular chemistry can be applied to 
the design of new pharmaceutical materials affording new compositions of matter with 
desirable composition, structure and properties. 
The design of a two-molecule, or binary, compound using complementary 
molecules represents an example of an application of crystal engineering. Crystal 
engineering is the understanding of intermolecular interactions, in the context of crystal 
packing, in the design of new solid materials.  By identifying reliable connectors through 
molecular recognition or self-assembly, one can build predictable architectures. 
 The study of supramolecular synthesis was accomplished using known 
pharmaceutical molecules such as Nifedipine (calcium channel blocker used for 
cardiovascular diseases) and Phenytoin (used as an anticonvulsant drug) and model 
compounds containing synthons common in pharmaceutical drugs (Crown ethers and 
 viii
Trimesic acid with ether linkages and carboxylic acid dimers, respectively) with 
complementary molecular additives. 
  The co-crystals formed were characterized by various techniques (IR, m.p., XPD, 
single X-ray diffraction) and preliminary results were found to exhibit characteristics 
different from the parent compounds as a direct result of hydrogen bonding and self-
assembly interactions.  These crystalline assemblies could afford improved solubility, 
dissolution rate, stability and bioavailability. 
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Chapter 1 
Introduction 
 
1.1  Supramolecular Chemistry and Crystal Engineering 
 
 The concept of crystal engineering was introduced by Pepinsky in 19551 and was first 
applied by Schmidt in the context of covalent bond formation in the solid state, i.e. 
topochemical reactions.2  More recent developments have expanded this concept into 
areas as diverse as supramolecular synthesis, crystal structure analysis and prediction.3,4  
Crystal engineering is a field that offers varying paths for the rational design of functional 
solids. 
 Supramolecular synthesis offers a paradigm for the facile design and isolation of 
supramolecular complexes using self-assembly of different, but complementary 
supramolecular synthons.  The subsequent ability to generate a diverse range of multiple 
component crystalline solids affords new compositions of matter and an ability to engage 
in systematic analysis of the factors that control structure/function relationships in the 
solid state. 
 Self-assembly of pre-selected molecular components,5 or supramolecular synthesis,4,6 
represents a paradigm for the generation of chemical structures with nanoscale features.  
Supramolecular synthetic approaches offer a number of attractive features: the ability to 
exploit readily available molecules or ions in novel ways, their inherent modularity  
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affords compositional and structural diversity, and the use of non-covalent interactions 
(such as ion-ion, ion-dipole, dipole-dipole, π-π stacking, Van der Waals forces and 
hydrogen bonding) makes for facile synthesis.  Supramolecular synthesis offers a 
combinatorial type of approach to synthesis of new structures and can afford a wide range 
of structural diversity without the need to break and form covalent bonds.  The paradigm 
is exemplified by the use of geometric considerations to guide the preparation of 
nanoscale hydrogen bonded polyhedra7 and by development of rational approaches to the 
design of ternary structures.The fact that hydrogen bonds are formed in a hierarchical 
fashion (strongest H-bond acceptor to strongest H-bond donor, and so on) and that crystal 
stability depends on specific intermolecular interactions8 is the basis for this arrangement. 
(a)
(b)
 
 (c)
 
Figure 1. Schematic representation of (a) supramolecular homosynthon (i.e. carboxylic acid dimer), (b) 
supramolecular heterosynthon (i.e. a carboxylic acid- pyridyl dimer), (c) supramolecular heterosynthon (i.e. 
ether linkage-amine). 
 
1.2  Supramolecular Synthons 
 Supramolecular synthons6 depict the possible ways in which complementary 
functionalities of molecules interact by non-covalent interactions.  One of such 
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interactions is the hydrogen bond.  A hydrogen bond is a strong, directional, selective and 
stabilizing interaction between a hydrogen atom and an electronegative atom.  As 
revealed by Figure 1, supramolecular synthons can either be self-complementary (a 
supramolecular homosynthon such as a carboxylic acid dimer9) or the result of 
complementary interactions between different moieties (a supramolecular heterosynthon 
such as a DNA base pair or the well-known carboxylic acid-pyridyl interaction10).  The 
latter brings with it the opportunity to build multiple component superstructures and is 
the main focus of this study. 
 
1.3  Polymorphism 
 The occurrence of polymorphism in crystal engineering cannot be ignored.  
Polymorphism is defined as the phenomenon where the same chemical substance exists 
in different crystalline forms or different crystalline patterns.11   This trend is more 
common among molecules with flexible conformations capable of hydrogen bonding.6   
The internal arrangement of molecules in the solid state has a pronounced influence on 
chemical and physical properties.  In this context, the existence of more than one 
crystalline form of a given compound, typically in the form of polymorphs or solvates, 
represents both a problem and an opportunity12 in organic synthesis and early stage 
development of pharmaceuticals.   
  Supramolecular synthons are the structural units within molecules, which can be 
formed and/or assembled by synthetic operations6.  The supramolecular synthons present 
in polymorphic forms may be intact from form to form, therefore it can be stated that the 
supramolecular equivalents of structural isomers are crystalline polymorphs6. The criteria 
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for assessing the existence of polymorphs are different unit cell parameters, crystal 
packing arrangements and physical properties.11 
    The study of the phenomenon of polymorphism has many implications.  It has 
increased due to the “great importance of legal and regulatory issues” that faces the 
pharmaceutical industry to date.13  The US Patent Office permits a new phase (i.e. 
polymorph, solvate or binary compound) of a drug to be patented if there is any 
processing or bioavailability benefit to the new solid phase.  This may be problematic 
since many drug molecules are prone to polymorphism and crystal size and morphology 
can vary for any given phase.  This can have significant commercial relevance because 
patents can be extended or effectively voided, translating into monetary gain or loss.  
 
1.4  Cambridge Structural Database 
 As previously stated, crystal engineering and supramolecular chemistry are 
intricately intertwined and the common theme between the two is the connection between 
structure and architecture control via intermolecular interactions, namely hydrogen 
bonding between supramolecular synthons.  Self-assembly of the targeted synthons 
through hydrogen bonding of complementary functional groups contributes to the control 
and possible prediction of the supramolecular structure, thus changing the physical 
properties of the material. Rationalization and design of these supramolecular solids is 
the basis of crystal engineering.  A survey of existing supramolecular synthons and 
structures can be carried out through the Cambridge Structural Database (CSD).14  By 
analyzing the existing structures and/or synthons in the CSD, new compositions of matter 
can be obtained, achieving new phases with new properties.  An extensive analysis of the 
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supramolecular synthons involved in the compounds described in this thesis was carried 
out and a library with average hydrogen bond distances was formulated.  The CSD has a 
total of 296,427 hits as of July 2003.  Out of the 296,427 hits, 127,003 hits are considered 
organic, and out of that subset, 118,322 are organics with no metals, which accounts for 
~40% of the total hits in the CSD.14  All searches had as search parameters R factor 
<0.075, no ions and organics only.    All searches were done with specific hydrogen bond 
distances, which were narrowed down through statistics and histograms.  The distances 
ranged from the two non-hydrogen atoms “sharing” the hydrogen atom since the 
hydrogen atom cannot be given a specific position due to its movement.   
 
Nifedipine Synthons 1.4.1 
N
O
O
H NN H N O H NO
O H N
 
  1         2           3        4 
 
Figure 2. Supramolecular synthons in nifedipine 
 
Table 1  Nifedipine Hydrogen bonded synthons and distances. 
  # hits distance min Max ave std Single* Multi* 
1 147 2.8-3.25 2.801 3.247 3.074 0.1186 122 25 
2 55 2.8-3.4 2.847 3.391 3.148 0.1313 48 7 
3 244 2.8-3.3 2.806 3.298 3.006 0.1172 224 20 
4 118 2.8-3.1 2.801 3.097 2.917 0.0752 106 15 
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on 
the same molecules (single) or the formation between  two molecules (multi) with complementary 
synthons. 
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 Nifedipine has three possible hydrogen-bonding sites, the secondary amine (H-bond 
donor), the ester carbonyl (H-bond acceptor) and the nitro group (H-bond acceptor).  Out 
of these three possible sites, the secondary amine is involved in hydrogen bonding most 
often and there are many more structures or hits of this interaction in the CSD as can be 
seen above.  A secondary amide is involved in all of the CSD searches that were carried 
out in the nifedipine analysis.  The ester carbonyl and the nitro group form secondary 
hydrogen bonds.  nifedipine will always be involved in a heterosupramolecular synthon.  
The use of the secondary amine as a designing tool seems promising since interactions 
with this functional group is very prevalent in the CSD. 
 
Phenytoin Synthons 1.4.2 
N H NO H N
O
N
H
N
H
O
O
X
X
H N
X
X
               1                                           2                                               3                               4 
Figure 3.  Supramolecular synthons in phenytoin 
 
Table 2.   Phenytoin Hydrogen bonded synthons and distances. 
  # hits Distance min max mean σ Single* Multi* 
1 970 2.4-3.3 2.707 3.297 2.908 0.1015 804 166 
2 340 2.7-3.2 2.701 3.2 2.939 0.1195 283 57 
3 1441 2.7-3.2 2.7 3.198 2.924 0.1014 1224 217 
4 147 2.8-3.25 2.801 3.247 3.074 0.1186 122 25 
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on 
the same molecules (single) or the formation between two molecules (multi) with complementary synthons. 
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 Phenytoin has two hydrogen bond donors (secondary amine) and acceptors 
(carbonyls) and they are complementary with one another as seen from the CSD searches.  
Search number 2 is a subset of search 3 and makes the results more relevant toward 
phenytoin.  Phenytoin can hydrogen bond as amide dimers or as heterosynthons between 
complementary functional groups or synthons present on different molecules.  As seen in 
the table above, the amide dimer is prevalent in structures containing the same molecule 
and the average distance is very similar when considering other ways of forming 
synthons. 
Crown Ethers Synthons 1.4.3 
O H N
X
O H N
H
O H N
N  
        1                                         2                                       3 
O H N O H N
X
+    18C6
  
4                 5                   
Figure 4.   Supramolecular synthons in crown ethers 
 
Table 3.  Possible ether hydrogen bonded synthons and distances. 
  # hits distance min max ave std Single* Multi* 
1 473 2.8-3.35 2.801 3.349 3.112 0.1319 328 141 
2 225 2.8-3.35 2.801 3.348 3.103 0.1256 133 92 
3 36 2.8-3.35 2.801 3.345 3.084 0.1226 26 10 
4 446 2.8-3.35 2.801 3.349 3.114 0.1323 319 127 
5 21 2.8-3.35 2.801 3.314 3.062 0.1246 21 0 
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on 
the same molecules (single) or the formation between  two molecules (multi) with complementary 
synthons. 
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 Crowns ethers are deficient in hydrogen bond donors; therefore they are very 
susceptible to forming hydrogen bonds when molecules with amines or any other 
complementary hydrogen bonding functional group are present.   Searches 2, 3 and 4 are 
all subsets of search 1.  Search 1 encompasses all possibilities, from primary amines, 
secondary amides, pyridines, etc.  Most of the structures or hydrogen-bonded synthons 
found in the CSD regarding ethers involved the same molecule.  On the contrary, when 
18-crown-6 (18C6) was specified as the ether to be analyzed, none of the 21 hits involved 
single molecules since 18C6 only has hydrogen bond donors.  In this case, molecules 
with complementary functional groups for hydrogen bonding were needed.  This is an 
example of how new phases and compositions of matter can be manipulated or designed 
in order to achieve different physical properties. 
 
Trimesic acid Synthons 1.4.4 
                                           
O
OH O
OH
 
                                                                  1 
Figure 5.   Supramolecular synthons in trimesic acid 
Table 4.  Trimesic acid carboxylic acid dimer hydrogen bond distances 
  # hits distance min max ave std Single* Multi* 
1 1193 2.4-3.2 2.554 3.196 2.657 0.0644 1059 134 
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on 
the same molecules (single) or the formation between  two molecules (multi) with complementary 
synthons. 
 
 Trimesic acid forms honeycomb networks by means of carboxylic acid dimers.  The 
carboxylic acid dimer is the basis for all of the TMA structures that will be discussed in 
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Chapter 5.  There are many forms of TMA and all involve the carboxylic acid dimer.  
The new structures incorporate a neutral guest in the cavities formed by six trimesic acid 
molecules bonding in a honeycomb fashion (~14Å pore diameter).  The distances of the 
hydrogen bonds between the carboxylic acid functional groups on separate molecules are 
very consistent when it comes to the network.  
 
1.4.5  Secondary Hydrogen Bonds  
 
                      
H
H
H
X N H O
X
X
 
                                     1                                                         2 
Figure 6.  Secondary hydrogen bonds involving methyl hydrogens and hydrogen bond acceptors nitrogen 
and oxygen. 
 
 
 There are two secondary hydrogen bonds which need to be specified since they are 
used to further stabilize the crystal packing of the supramolecular structures discussed in 
this work.  Synthon 1 is seen in the nifedipine/4,4’-dipyridyl structure while synthon 2 is 
seen in the phenytoin/trans-1,2-(4-pyridyl) ethylene structure.  Further discussion on all 
of these structures will be available in the following chapters.  
 
Table 5.  Possible secondary hydrogen bond synthons and distances 
  # hits distance min max ave std Single* Multi* 
1 10317  3.3-4.2 3.4  3.199 3.8872 0.1038 8606  1711  
2 13921 3.35-4.2 3.349 4.199 3.8976 0.1995 11766 2155 
*Single and multi-component corresponds to the homo/heterosynthons being formed by the synthons on 
the same molecules (single) or the formation between  two molecules (multi) with complementary 
synthons. 
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This thesis is based on the principles of crystal engineering in order to generate 
new compositions of matter through supramolecular synthesis and self-assembly of 
complementary synthons.  This presents an increase in the potential need to control solid-
state structures, changing their physical properties and leading to improved solubility and 
bioavailability.  The study chose pharmaceutical molecules as the target system since 
they contain a wide range of synthons and understanding of the crystal structure – 
physical property relationship is essential for the continued application of these essential 
chemicals toward improving the overall health of society. 
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Chapter 2 
 
Nifedipine 
 
2.1  Description 
 
 
N
H
NO2
COOCH3H3COOC
CH3CH3
 
 
Figure 7.  Pure nifedipine stick models.  Oxygen atoms are in red (hydrogen bond acceptor); nitrogen atoms 
are in blue (hydrogen bond donor).  All hydrogen atoms on the figure to the right have been omitted for 
clarity. 
 
 
 Nifedipine,15 with MW of 246.34g/mol and m.p. of 172-174°C, is a calcium 
antagonist used in the treatment of cardiovascular disorders such as hypertension and 
angina pectoris.  Nifedipine exhibits low water solubility (less than 10µg/mL) and erratic 
bioavailability.  There is a direct correlation between structure and function of new 
pharmaceutical phases of nifedipine.  Modifying the structure of the compound, thus 
creating new and different phases, may affect different properties.  Differing the phases 
or crystalline self-assemblies of nifedipine may improve the drug's solubility, dissolution 
rate, stability and bioavailability.  
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 Dihydropyridine chemistry16 began in 1882 when Hantzsch first reported 
dihydropyridines as stable intermediates in the pyridine synthesis that bears his name.  
The recent interest in dihydropyridines can be traced to the coenzyme reduced 
nicotinamide adenine dinucleotide (NADH) and the unique ability of this compound in 
biological systems to reduce unsaturated functional groups.15  In 1949 A.P. Phillips 
reported on the weak analgesic and curare-like activities of a few dihydropyridine 
derivatives.  In the search for orally active drugs for the treatment of coronary 
insufficiency, F. Bosset synthesized in 1966 a compound designated Bay a 1040, which 
following its introduction as nifedipine in 1975 has since become one of the major 
cardiovascular drugs.  
 Nifedipine16 is sensitive to light in solid form and extremely sensitive to light in 
dissolved state in solution.  In the crystal lattice, the almost flat dihydropyridine ring lies 
at a practically perpendicular angle to the nitrophenyl group, the ortho-nitro group facing 
away from the dihydropyridine ring.  Under the influence of visible and ultra-violet light 
nifedipine in solutions is converted into a nitroso compound.  
 
2.2 Strategy 
 In view of the fact that nifedipine contains hydrogen bond acceptors and donors, 
complementary molecules can be compounds with both acceptor and donor synthons.  
The main hydrogen-bonding site is the secondary amine, which can bond to carbonyl as 
well as nitrogen (e.g. pyridines). 
  Crystals of A, B and C were obtained via slow evaporation of stoichiometric amounts 
of nifedipine and cocrystal formers in the appropriate solvents.  All crystallization 
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experiments were conducted in an unmodified atmosphere and the solvents were dried by 
standard methods prior to use. All chemicals used are commercially available and were 
purchased from Aldrich®.  
 
Table 6.  Nifedipine Supramolecular Complexes 
 
Nifedipine/formamide A 
Nifedipine/isonicotinamide B 
Nifedipine/4,4'-dipyridyl C 
 
 
 
 
NH2
O
H
N
NH2
O
N N
  FORMAMIDE                  ISONICOTINAMIDE                       4,4'-DIPYRIDYL  
 
 
Figure 8.  Structures of the co-crystal formers used in the supramolecular complexes involving nifedipine. 
 
 
2.3  Structures 
 
2.3.1  Nifedipine/formamide (A) 
 
Crystallization of nifedipine from formamide results in a 1:1 supramolecular 
complex that is sustained by amine-carbonyl H-bonds. In A, as revealed by Figure 3 
(synthons 3), one of the hydrogen atoms in the amino moiety of the formamide hydrogen 
bonds to the carbonyl oxygen of the ester on one nifedipine molecule with bond distance 
of 3.024Å, which falls well within the distance range found in the CSD and stated in 
chapter 1 (nifedipine search 3) of 2.8-3.3 Å.  The other amine hydrogen atom found in 
formamide is engaged in a hydrogen bond with the nitro oxygen on another nifedipine 
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molecule.  The distance for this bond is 3.155 Å and falls within the range obtained from 
the CSD search (nifedipine search 2) for this synthon (2.8-3.4 Å).  Formamide has two 
hydrogen bond donors (the amine hydrogens) but also has a hydrogen bond acceptor (the 
aldehyde carbonyl).  The carbonyl is also involved in a hydrogen bond with a third 
nifedipine molecule.  The carbonyl is bonded to the secondary amine of the nifedipine 
molecule and has a distance of 2.906 Å and falls within the range set from the CSD 
search (nifedipine search 4) of 2.8-3.1 Å.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.  The 1:1 adduct formed between nifedipine and formamide.  The hydrogen-bonded motif is also 
shown. 
 
 
2.3.2  Nifedipine/isonicotinamide (B) 
 
Crystallization of nifedipine and isonicotinamide from methanol results in a 1:1 
supramolecular complex that is sustained by amine-carbonyl and amine-pyridine H-
bonds. In B, as revealed by Figure 4, one of the hydrogen atoms in the amino moiety of 
the Isonicotinamide hydrogen bonds to the carbonyl oxygen of the ester on one nifedipine 
molecule with bond distance of 3.097Å which falls well within the distance range found 
in the CSD and stated in chapter 1 (nifedipine search 3) of 2.8-3.3 Å.  The other amine 
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hydrogen atom found in isonicotinamide is engaged in a hydrogen bond with another 
isonicotinamide molecule.  The distance for the amine hydrogen and the pyridine 
nitrogen bond on separate isonicotinamide molecules is 2.911 Å and falls within the 
range obtained from the CSD search (nifedipine search 1) for this synthon (2.8-3.25 Å). 
Isonicotinamide has two hydrogen bond donors (the amine hydrogens) but also has a 
hydrogen bond acceptor (the amide carbonyl).  This carbonyl oxygen is involved in a 
hydrogen bond to a second nifedipine molecule.  The carbonyl is bonded to the secondary 
amine of the nifedipine molecule and has a distance of 2.878 Å and falls within the range 
set from the CSD search (nifedipine search 4) of 2.8-3.1 Å.   B differs from A in that a 
new synthon is involved, the amine-pyridine hydrogen bond is seen in B which facilitates 
many more arrangements and new phases for nifedipine. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  The 1:1 adduct formed between nifedipine and isonicotinamide. 
 
 
 
 
2.3.3 Nifedipine/4,4’-dipyridyl (C) 
 
 Crystallization of nifedipine and 4,4’-dipyridyl from methanol results in a 1:1 
supramolecular complex which is sustained by amine-pyridine H-bonds.  4,4’-dipyridyl is 
only a hydrogen bond acceptor; therefore the secondary amine in the nifedipine is the 
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most likely hydrogen bonding site. In C, as revealed by Figure 5, the amine-pyridine 
hydrogen bond is evident with a bond distance of 3.134Å.  This distance does fall within 
the nifedipine CSD search from chapter 1 (search 1, 2.8-3.25 Å).  A secondary hydrogen 
bond is formed between one methyl hydrogen (from the ester group) and the other 
pyridine nitrogen available. This bond’s purpose is for stability in the crystal packing and 
the distance is 3.295 Å.  The range distance for this secondary hydrogen bond is 3.3-4.2 
Å; therefore, it is on the lower limit of this type of bond (Search 1, section 1.25).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  The 1:1 adduct formed between nifedipine and 4,4’-dipyridyl. 
 
 
2.4 
2.4.1 
 Synthesis and Results 
 
Nifedipine/formamide (A) 
 
Synthesis:  In a typical reaction, 32 mg (1.29x10-4 mol) of nifedipine was dissolved in 2 
mL of formamide.  The reaction vial was kept tightly capped to avoid any solvent 
evaporation.  The vial was covered in aluminum foil to protect from light.  In 
approximately two days yellow crystals appeared. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix A 
 
Crystal packing: Crystallization of nifedipine from formamide results in a 1:1 
supramolecular complex that is sustained by amine-carbonyl H-bonds.  Distances range 
between 3.024-3.155Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3443, 3303 cm-1 (N-H stretch, 1° 
amine, formamide); 1684 cm-1  (C=O stretch, formamide) 1310, 1248, 1217 cm-1 (C-O 
stretching). 
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Melt-temp: 136-138°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single crystal data; 
experimental (simulated): 8.461(8.850), 9.955(9.923), 12.682(12.893), 13.080(13.420), 
14.954(15.307), 16.966(17.022), 17.082 (17.034), 21.036(20.827), 23.539(23.437), 
24.658(24.682), 26.725(26.715), 27.039(27.028). 
 
 
2.4.2 
2.4.3 
Nifedipine/isonicotinamide (B) 
 
Synthesis:  In a typical reaction, 31 mg (1.26x10-4 mol) of nifedipine and 28 mg 
(2.29x10-4 mol) of isonicotinamide were dissolved in approximately 1 mL of methanol.  
Slow evaporation of the solvent for approximately a week yielded 1:1 crystals.  The 
reaction vial was covered in aluminum foil to prevent light degradation. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix A 
 
Crystal packing: Crystallization of nifedipine and isonicotinamide from methanol results 
in a 1:1 supramolecular complex that is sustained by amine-carbonyl and amine-pyridine 
H-bonds. Distances range between 2.878-3.097Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3408 cm-1 (N-H stretch, 2° amine); 
3286 cm-1 (-OH stretch); 1669 cm-1 (C=O stretch);  1209, 1118 cm-1 (C-O stretching). 
 
Melt-temp: 148-153°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single crystal data; 
experimental (simulated): 10.418(10.636), 11.561(11.823), 11.880(11.849), 
13.003(13.212), 19.404(19.739), 19.660(19.771), 21.142(21.167), 22.739(22.779), 
23.739(23.774), 26.399(26.407), 31.820(31.806). 
 
 
Nifedipine/4,4’-dipyridyl (C) 
 
Synthesis:  In a typical reaction, 30 mg (1.22x10-4 mol) of nifedipine and 43 mg 
(2.75x10-4 mol) of 4,4’-dipyridyl were dissolved in approximately 1 mL of methanol.  
Slow evaporation of the solvent for approximately two week yielded 1:1 nifedipine/4,4’-
dipyridyl crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix A 
 
Crystal packing: Crystallization of nifedipine and 4,4’-dipyridyl from methanol results in 
a 1:1 supramolecular complex that is sustained by amine-pyridine H-bonds.  4,4’-
Dipyridyl is only a hydrogen bond acceptor; therefore the secondary amine in the 
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nifedipine is the most likely hydrogen bonding site.  Distances range between 3.134-
3.295Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3275 cm-1 (N-H stretch, 2° amine); 
3213 (-OH stretch); 1687 cm-1 (C=O stretch); 1263, 1208 cm-1 (C-O stretching). 
 
Melt-temp: 137-139°C 
 
X-ray powder diffraction:  experimental done, calculated could not be done.  4.039, 
11.459, 12.281, 19.362, 20.200, 21.601, 24.802, 24.958, 25.340, 25.419. 
 
 
2.5 Discussion 
 
Presented above were three examples of the use of supramolecular synthesis to 
generate new compositions of matter containing molecules of interest to materials 
scientists.  These supramolecular complexes show how secondary amines, nitro groups 
and carbonyls present in pharmaceutical drugs can be exploited via crystal engineering.  
This has increased the potential to control solid-state structures, changing their physical 
properties and leading to improved solubility and bioavailability.  Pure nifedipine H-
bonds forming a chain, secondary amine to ether carbonyl, but as seen in the previous co-
crystals, other synthons are exploited and the crystal structure therefore has to adjust.  
Careful analysis of the existing supramolecular synthons on nifedipine provides an 
educated guess that allows scientists to choose other molecules with complementary 
components, designing supramolecules.  The exact connection sites for the synthons 
cannot always be predicted since other factors such as solvent, sterics and number of 
possible hydrogen bonding sites has a powerful effect on the outcome. 
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Chapter 3 
 
Phenytoin 
 
 
3.1.  Description 
 
 
N
N
O
H
O
H
 
Figure 12.  Pure phenytoin stick models.  Oxygen atoms (in red) are the hydrogen bond acceptors and the 
nitrogen atoms (in blue) are the hydrogen bond donors.  Hydrogen atoms have been deleted for clarity. 
 
 
 Phenytoin,17 or 5,5-diphenylhydantoin, is a pharmaceutical drug used for the 
treatment of seizures.  It is sparingly soluble in water (20-25mcg/mL).  Compounds with 
aliphatic side groups at position C5 are commonly used as sedatives, and phenyl rings at 
this position lead to anticonvulsant properties without the need to impair consciousness.  
It is also sparingly soluble in ethanol and acetone and has a M.W. of 252.272g/mol and 
m.p. of 295°C.  According to Chakrabati,18 phenytoin exists in two forms.  Form 1: 
rodlike plates or regular crystalline shape, and form 2: needle shaped.  The existence of 
these two forms is due to differences in the crystalline state. 
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 In 1938 Merrit and Putnam19 found that 5,5-diphenylhydantoin (phenytoin) showed 
anticonvulsant properties.  Twelve years later it was stated that apart from antiepileptic 
activity, phenytoin possessed antiarrhythmic activity.  It belongs to class 1b according to 
Vaughan Williams classification of antiarrhythmic agents modulating voltage-gated 
sodium channels conductance.  Limited clinical effectiveness and undesired side effects 
are the driving force to using supramolecular chemistry in order to change the structure, 
therefore changing the physical properties since there is a direct correlation between the 
two.   
 Diphenylhydantoin and phenobarbital are the most widely used drugs in the treatment 
of grand mal, psychomotor, and focal epilepsies.  The similarity of barbiturates to uracil 
has prompted investigations into their hydrogen-bonding capabilities with adenine 
molecules. Some of the biological effects of these drugs may derive from an ability to 
specifically bind and inactivate adenine-containing nucleic acids or coenzymes.20   
Comparisons of the complexes formed by these drugs with adenine containing molecules 
may prove helpful in understanding the modes of action of these drugs.20 
 
 
 
 
 
 
 
 
 
Figure 13.  Hydrogen bonded motif of pure phenytoin. 
 
 The crystals are orthorhombic and systematic absences indicate space groups Pnma or 
Pn21a.  Pn21a (centrosymmetric space group), indicated by structure analysis, was yielded 
by the hydantoin group atomic positions even though the true space group for phenytoin 
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is non-centrosymmetric, but the proximity of the hydantoin group plane was very close to 
0 or π (approximating a centrosymmetric arrangement in the unit cell).  The hydrogen-
bonded motif, figure 2, shows the hydrogen bonds between amine hydrogens and 
carbonyl oxygens between phenytoin molecules with distances ranging from 2.784-2.844 
Å.  These distances fall within the range obtained from the CSD search in Chapter 1 
(phenytoin search 2) which is 2.7-3.2 Å.   
 
3.2   Strategy 
 
In view of the fact that phenytoin has both hydrogen bond acceptors (carbonyl 
oxygens) as well as hydrogen bond donors (secondary amines), a complementary 
molecule can be one that has at least one hydrogen bond acceptor moiety (example 
amines, alcohols, carboxylic acids, etc.) or at least one hydrogen bond donor moiety 
(amines, amides, alcohols, etc).  Phenytoin has the added characteristic that it can form 
amide dimers between two phenytoin molecules since the synthon is complementary with 
itself. 
Crystals of A, B, and C were obtained via slow evaporation of stoichiometric amounts 
of phenytoin and cocrystal formers in the appropriate solvents.  All crystallization 
experiments were conducted in an unmodified atmosphere and the solvents were dried by 
standard methods prior to use. All chemicals used are commercially available and were 
purchased from Aldrich®.  
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Table 7.  Phenytoin Supramolecular Complexes 
Phenytoin/4(1H) pyridone A 
Phenytoin/4,4'-dipyridyl B 
Phenytoin/trans-1,2-bis(4-pyridyl) ethylene  C 
 
 
N
H
H H
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O
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N
   4(1H)-PYRIDONE                            4,4'-DIPYRIDYL                       TRANS-1,2-BIS(4-PYRIDYL)ETHYLENE
 
Figure 14.  Structures of the co-crystal formers used in the supramolecular complexes involving phenytoin. 
 
 
 
3.3  Structures 
 
3.3.1  Phenytoin/4(1H)-pyridone (A) 
 
Crystallization of phenytoin and 4-hydroxypyridine (which later tautomerized to 
4(1H)-pyridone) from ethanol results in a 1:1 supramolecular complex that is sustained 
by amine-carbonyl H-bonds between phenytoin molecules and pyridone molecules. In A, 
as revealed by Figure 4, there is a chain formed of phenytoin molecules.  The pyridones 
also arrange consecutively with one another forming another chain by means of N-
H…O=C bonds.  These hydrogen bonds average 2.665 Å, well within the range obtained 
from the CSD (2.7-3.2 Å).  These two independent chains, phenytoin and pyridone, are 
connected to each other by means of another N-H…O=C bond.  The carbonyl present in 
the pyridone molecule is bifurcated, H-bonding to both the secondary amine in phenytoin 
as well as the secondary amine in the pyridone molecule.  In the crystal packing of A one 
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can observe that two pyridone chains are sandwiched between two phenytoin chains.  If 
one examines figure 2 one can see how that motif was simply expanded enough to fit the 
two H-bonded pyridone chains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  The 1:1 adduct formed between phenytoin and 4(1H) pyridone.  The hydrogen bonded crystal 
packing is shown to the left. 
 
 
3.3.2 Phenytoin/4,4’-dipyridyl (B) 
 
Crystallization of phenytoin and 4,4’-dipyridyl from 2,4-pentanedione results in a 1:1 
supramolecular complex that is sustained by amine-pyridine H-bonds between the 
phenytoin and 4,4’-dipyridyl (Bipy) molecules as well as phenytoin amide dimers. In B, 
(Figure 5) there is a chain of phenytoin and bipy molecules formed.  The N-H…N 
distance is 2.861Å and falls within the distance range obtained from the CSD search in 
Chapter 1 (phenytoin search 4), which is 2.8-3.25 Å.  The phenytoin molecules also H-
bond and form amide dimers.  The hydrogen bond distance between the N-H….O=C 
dimers on separate phenytoin molecules is 2.791 Å and according to the information 
obtained from the CSD searches on Chapter 1 (phenytoin search 1) fall within the 
distance range of 2.4-3.3Å.  The phenytoin molecules arrange in dimers and the 
secondary amine not involved in the dimer is available to H-bond to the pyridine nitrogen 
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of the 4,4’-dipyridyl, forming a zigzag chain.  The other carbonyl is not involved in any 
other hydrogen bonds.  The crystal packing of this supramolecular structure orients the 
hydrophobic phenyl rings on the inside of the chains, keeping the hydrophilic parts of the 
structure on the outside and susceptible to forming bonds with complementary synthons 
(figure 5). 
 
 
 
 
 
 
 
 
 
 
Figure 16.  The 1:1 adduct formed between phenytoin and 4,4’-dipyridyl.  The hydrogen bonded crystal 
packing is shown. 
 
3.3.3 Phenytoin/trans-1,2-bis(4-pyridyl) ethylene (C) 
 
 Crystallization of phenytoin and trans-1,2-bis(4-pyridyl) ethylene from 2,4-
pentanedione results in a 1:5 supramolecular complex that is sustained by amine-pyridine 
H-bonds between the phenytoin and trans-1,2-bis(4-pyridyl) ethylene molecules as well 
as dimers between the phenytoin amides. In C (Figure 6), there is a chain formed of 
phenytoin and trans-1,2-bis(4-pyridyl) ethylene molecules.  The N-H…N distance is 2.844 
Å and falls within the distance range obtained from the CSD search on Chapter 1 
(phenytoin search 4) which is 2.8-3.25 Å.  The phenytoin molecules also H-bond and 
form amide dimers.  The hydrogen bond distance between the N-H….O=C on separate 
phenytoin molecules is 2.891 Å and according to the information obtained from the CSD 
searches on Chapter 1 (phenytoin search 1) falls within the distance range of 2.4-3.3Å.  
Structure C is very similar to structure B in its hydrogen bonding, the only difference is 
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that in addition to forming dimers between the phenytoin molecules and N-H…N bond to 
the additive, there are also additives interacting in a secondary hydrogen bond with the 
available phenytoin carbonyl.  The bond distance is 3.386 Å and falls within the range for 
the CH…O carbonyl synthon (range 3.1-3.9 Å).  This hydrogen bond permits the trans-
1,2-bis(4-pyridyl) ethylene to stay in the cavity.   
The phenytoin molecules arrange in dimers and the secondary amine not involved in 
the dimer is available to H-bond to the pyridine nitrogen of the trans-1,2-bis(4-pyridyl) 
ethylene, forming a zigzag chain.  The crystal packing of this supramolecular structure 
arranges in such a way that allows for the accommodation of an additive molecule in the 
hydrophobic cavity. 
  
 
 
 
 
 
 
 
 
 
Figure 17.  The 1:5 adduct formed between phenytoin and trans-1,2-bis(4-pyridyl) ethylene.  The hydrogen 
bonded crystal packing is shown. 
 
 
3.4  Synthesis and Results 
 
3.4.1 Phenytoin/4(1H)-pyridone (A) 
 
Synthesis:  In a typical reaction, 28 mg (1.11x10-4 mol) of phenytoin and 11 mg 
(1.16x10-4 mol) of 4-hydorxypyridine (which later tautomerizes to 4(1H)pyridone) were 
dissolved in approximately 2 mL ethanol and 1 mL acetone.  The reaction vial was kept 
tightly capped to avoid solvent evaporation.  After a few weeks clear 1:1 crystals formed. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix B 
 
Crystal packing: Crystallization of phenytoin and 4-hydroxypyridine (which later 
tautomerized to 4(1H)-pyridone) from ethanol results in a 1:1 supramolecular complex 
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that is sustained by amine-carbonyl H-bonds between phenytoin molecules and pyridone 
molecules.  Distances averaged 2.665Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3311 cm-1 (N-H stretch, 2° amine, 
phenytoin); 1758, 1711, 1497cm-1 (C-O stretching). 
 
Melt-temp: 234-239°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single crystal data; 
experimental (simulated): 5.336(5.212), 11.332(11.137), 15.250(15.097), 16.419(16.228), 
17.000(17.763), 17.977(18.019), 19.364(19.362), 19.679(19.821), 20.055(20.341), 
21.417(21.160), 23.724(23.341), 26.348(26.054), 26.628(26.418), 27.643(27.260), 
29.868(29.479). 
 
 
3.4.2 Phenytoin/4,4’-dipyridyl (B) 
 
Synthesis:  In a typical reaction, 28 mg (1.11x10-4 mol) of phenytoin and 19 mg 
(1.22x10-4 mol) of 4,4’-dipyridyl were dissolved in approximately 1 mL of 2,4-
pentanedione.  Slow evaporation of the solvent for a few weeks yielded 1:1 crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix B 
 
Crystal packing: Crystallization of phenytoin and 4,4’-dipyridyl from 2,4-pentanedione 
results in a 1:1 supramolecular complex that is sustained by amine-pyridine H-bonds 
between the phenytoin and 4,4’-dipyridyl (bipy) molecules as well as phenytoin amide 
dimers.  Distances range between 2.791-2.861Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).   N/A 
 
Melt-temp: 225-227°C 
 
X-ray powder diffraction:  experimental done, calculated could not be done.  12.974, 
17.461, 18.798, 20.613, 22.180, 24.902, 26.717, 28.599, 31.931. 
 
 
 
 
3.4.3 Phenytoin/trans-1,2-bis(4-pyridyl) ethylene (C) 
 
Synthesis:  In a typical reaction, 29 mg (1.15x10-4 mol) of phenytoin and 108.35 mg 
(5.93x10-4 mol) of trans-1,2-bis(4-pyridyl) ethane were dissolved in approximately 1 mL 
2,4-pentanedione.  Slow evaporation of the solvent for approximately a week yielded 
yellow 1:5 crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix B 
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Crystal packing: Crystallization of phenytoin and trans-1,2-bis(4-pyridyl) ethane from 
2,4-pentanedione results in a 1:5 supramolecular complex that is sustained by amine-
pyridine H-bonds between the phenytoin and trans-1,2-bis(4-pyridyl) ethane molecules as 
well as dimers between the phenytoin.  Distances range between 2.844-3.273Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3264, 3194 cm-1 (N-H stretch, 1° 
amine); 3066, 3029 cm-1 alkenes; 1713 cm-1 (C=O stretch); 1310, 1248, 1209 cm-1 (C-O 
stretching), 985 cm-1 (aromatic hydrogens). 
 
Melt-temp: 254-257°C 
 
X-ray powder diffraction:  experimental done, calculated could not be done.  15.919, 
19.370, 19.866, 2.159, 22.089, 22.215, 23.815, 34.826, 36.701. 
 
 
 
3.5  Discussion 
 
Presented above were three examples of the use of supramolecular synthesis to 
generate new compositions of matter that contains molecules of interest to materials 
scientists.  These supramolecular complexes show how carbonyl and secondary amines if 
viewed separately, or known as amides if both synthons (functional groups) are viewed 
together, in pharmaceutical drugs can be exploited via crystal engineering.  This has 
increased the potential to control solid-state structures, changing their physical properties 
and leading to improved solubility and bioavailability.  Pure phenytoin makes full use of 
all available synthons when hydrogen bonding, forming a tape.  In the co-crystals, 
modifications to this hydrogen bonded motif are necessary when accommodating other 
complementary compounds.  Not all available synthons will be exploited, as see in 
structure A, where one of the two carbonyls available in each phenytoin molecule is not 
involved in a hydrogen bond with another phenytoin molecule, additive molecule or 
solvent molecule.  In structure B, the supramolecular tape found in pure phenytoin has 
been expanded to accommodate the bipy molecules.  Phenytoin molecules still hydrogen 
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bond to each other forming dimers.  One secondary amine is involved in the hydrogen 
bond with the bipy molecule, but the other carbonyl is not involved in a synthon (as seen 
with structure A).   Structure C is very similar to structure B, having the same hydrogen 
bonding with the additive and also an available carbonyl not involved in a hydrogen 
bond, but differs in that it fits another additive molecule in the cavities formed from the 
arrangements of the Phenytoin/trans-1,2-(4-pyridyl) ethylene chains.  This elucidates the 
fact that just because the same synthons are being used, does not mean that the same 
arrangements will be seen from structure to structure.  
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Chapter 4 
 
Crown Ethers 
 
4.1 Description 
 
Crown ethers are toxic compounds and serve as model compounds for 
pharmaceutical molecules that contain ether linkages.  Ether moieties are deficient in H-
bond donors and contain excess H-bond acceptors.  They are therefore predisposed to 
become involved in supramolecular heterosynthons and it should not be surprising that 
well known ethers such as 18-Crown-621 (18C6) and Dibenzo-18-Crown-622 (DB18C6) 
form co-crystals and solvates with complementary molecules.  Since the crown ether has 
only hydrogen bond acceptors (oxygen atoms), a complementary molecule should be one 
that has at least one hydrogen bond donor moiety (amines, alcohols, carboxylic acids, 
etc.).  The pure phase for 18C621 has been isolated, and the pure phase for DB18C6 has 
been solved, but is pending publication.   
O
O
O
O
O
O
 
 
Figure 18.  Pure Dibenzo-18-crown-6 stick models.  Oxygens (in red) are the hydrogen bond acceptors. 
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Figure 19. Pure 18-crown-6 stick models.  Oxygens (in red) are the hydrogen bond acceptors. 
 
 
4.2  Polymorphism 
 
The phenomenon of polymorphism in crystal engineering cannot be ignored.  
Polymorphism is defined as the phenomenon where the same chemical substance exists 
in different crystalline forms or different crystalline patterns.11   This phenomenon is more 
common among molecules with flexible conformations capable of hydrogen bonding.6  
Supramolecular synthons are the structural units within molecules, which can be formed 
and/or assembled by synthetic operations.6  The supramolecular synthons present in 
polymorphic forms may be intact from form to form, therefore it can be stated that the 
supramolecular equivalents of structural isomers are crystalline polymorphs.6  The 
criteria for assessing the existence of polymorphs are different unit cell parameters, 
crystal packing arrangements and physical properties.6 
 
4.3  Strategy 
    In view of the fact that the crown ethers only have hydrogen bond acceptors (oxygen 
atoms), a complementary molecule should be one that has at least one hydrogen bond 
acceptor moiety (example amines, alcohols, carboxylic acids, etc.).  A survey of the 
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Cambridge Structural Database (CSD) 14 shows that out of 362 hits (146 single-
component, 208 multi-component) for 18C6 foundation, 177 included metals, 39 had 
hydrogen bonding to amine groups, and the remaining 88 hits were of crown derivatives. 
The same trend was observed for DB18C6.  Out of the 26 hits (15 single-component, 11 
multi-component), 16 included metals, and only one hit had a hydrogen bond to an amine 
group.  The remaining three hits were DB18C6 derivatives.  No hits showed hydrogen 
bonding with amine groups and the remaining 13 hits were of crown derivatives. 
 Crystals of A, B, C, D, E, F, G, and H were obtained via slow evaporation of 
stoichiometric amounts of crown ether and cocrystal formers in the appropriate solvents.  
All crystallization experiments were conducted in an unmodified atmosphere and the 
solvents were dried by standard methods prior to use. All chemicals used are 
commercially available and were purchased from Aldrich®.  
 
Table 8.  Crown ether Supramolecular Complexes 
 
Dibenzo-18-crown-6/4-nitroaniline A 
Dibenzo-18-crown-6/2-methyl-4-nitroaniline B 
Dibenzo-18-C-6/nicotinamide Polymorph A  C 
Dibenzo-18-C-6/nicotinamide Polymorph B D 
18-crown-6/2,6-diaminopurine E 
18-crown-6/dicyandiamide F 
18-crown-6/5-aminoisophthalic acid G 
18-crown-6/tetrafluoroisophthalic acid/H2O H 
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Figure 20.  Structures of the co-crystal formers used in the supramolecular complexes. 
 
4.4  Structures 
4.4.1  Dibenzo-18-crown-6/4-nitroaniline (A) 
Crystallization of DB18C6 and 4-nitroaniline from benzene affords a 1:1 co-crystal, A. 
Grinding a 1:1 mole ratio of DB18C6 and 4-nitroaniline also forms the co-crystal. As 
revealed by Figure 4, the amine moiety forms H-bonds with four of the six ether oxygens 
and generates a supramolecular complex. The hydrogen bond distances between the 
oxygen atoms in the ether linkages closest to the aromatic rings and the bifurcated 
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hydrogens in the amino group range from 3.050-3.145Å, with the 4-nitroaniline bonded 
to the outside of the crown ether bowl.   
  
 
 
Figure 21. The 1:1 adduct formed between DB-18-C-6 and 4-nitroaniline.  
 
     These supramolecular complexes pack into tubular arrangements with solvent 
channels on the interior of the nanotubes (Figure 5).  The tubular structure is not 
sustained by π-π stacking or C-H…O- C hydrogen bonding.  The tubular arrangements are 
held together through steric effects. 
                                
Figure 22. Stick and space-filling models of one of the nanotubes formed by self-assembly of DB18C6/4-
nitroaniline.  The nanotubes have an exterior diameter of ca. 2.3nm and the solvent channels have an 
effective cross-section of 0.35nm. 
 
     The nature of the crystal packing is of particular note since the nanotubes are 
inherently polar and they crystallize parallel to one another.  Furthermore, as revealed by 
Figure 6, the 4-nitroaniline molecules are oriented at ca. 60o to the polar axis.  This 
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represents a close to ideal alignment of dipoles that in most systems is usually frustrated 
because of the tendency of molecules with high polarizability to pack in anti-parallel 
arrangements.23 
                               
(a) (b)
 
 
Figure 23. Views of the orientation of the p-nitroaniline molecules in 1: (a) parallel to the polar axis; (b) 
looking down the polar axis.   
 
4.4.2 Dibenzo-18-crown-6/2-methyl-4-nitroaniline (B) 
 
 
 
 
 
Figure 24. The 1:1 adduct formed between DB-18-C-6 and 2-methyl-4-nitroaniline. 
 
Crystallization of DB18C6 and 2-methyl-4-nitroaniline also results in a 1:1 
supramolecular complex that is sustained by amine-ether H-bonds. In B, as revealed by 
Figure 7, the amino moiety hydrogen bonds through the outside of the bowl to three 
oxygen atoms of the crown.  One amino hydrogen is bifurcated, the other is not.  The 
distances between the hydrogen atoms of the 2-methyl-4-nitroaniline and the oxygen 
atoms of the ether linkages range from 2.695-3.465Å.  However, in this case, non-
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centrosymmetric crystals are obtained.  The molecule contains a donor amine and an 
acceptor nitro group at the para position.  This positioning allows for maximum 
acentricity of the molecule.  A methyl group is substituted at the ortho position, which 
affects the non-centrosymmetric structure.  The methyl group may also act as weak H-
bond donor, but it is not evident in this case.24 
 
4.4.3 Dibenzo-18-crown-6/nicotinamide Polymorph A (C) 
     Nicotinamide,25 vitamin B3 and a well known hydrotropic agent, was chosen as a 
complementary additive to DB18C6 due to the presence of the amino group.  
Crystallization of DB18C6 and nicotinamide from THF results in a 1:1 supramolecular 
complex that is sustained by amine-ether H-bonds.  Nevertheless, this supramolecular 
organic solid is distinguished by the fact that it can form two crystalline phases that differ 
in how the amine moieties H-bond to the DB18C6 molecules.  In C, the amine group of 
the nicotinamide molecule is hydrogen bonded to the ether oxygens through the outside 
part of the crown bowl. The hydrogen bond distances between the hydrogen to the 
oxygen range from 3.134 to 3.362Å 
            
Figure 25.  Outside bowl polymorphic form of the 1:1 adduct formed between DB18C6 and nicotinamide.  
Crystal Packing of the 1:1 polymorphic co-crystals of DB18C6 and nicotinamide. 
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4.4.4  Dibenzo-18-crown-6/nicotinamide Polymorph B (D) 
In D the nicotinamide molecule is hydrogen bonded to the inside of the crown bowl 
with hydrogen bond distances ranging from 2.995 to 3.043Å.  A notable difference 
between the hydrogen bonding of the two polymorphic forms is the fact that in C, one 
hydrogen from the amino group bifurcates and bonds to two oxygen atoms closets to one 
benzene ring. 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  Inside bowl polymorphic form of the 1:1 adduct formed between DB18C6 and nicotinamide 
Crystal Packing of the 1:1 polymorphic co-crystals of DB18C6 and nicotinamide. 
   
 
 In D, each hydrogen atom from the amine is involved in a hydrogen bond with one 
of the oxygen atoms, not being the same two oxygen atoms as in C.  In the CSD,5 seven 
structures have been reported of co-crystals involving crown ethers [DB18C6 (1 
structure) and 18C6 (6 structures)] hydrogen bonded to amino groups. 
 
4.4.5 18-crown-6/2,6-diaminopurine (E) 
Crystallization of 18C6 and 2,6-diaminopurine from ethanol affords a 1:1 co-crystal, E.   
As revealed by Figure 11, co-crystal E is sustained by hydrogen bonds between the 
secondary amine hydrogen from the 2,6-diaminopurine molecule and an ether linkages 
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from the crown.  Two 2,6-diaminopurine molecules are involved in a dimer (NH2…N).  
The secondary amine is then H-bonded to a crown oxygen. Distances range between 
2.836-3.072Å. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27.  The 1:1 adduct of 18C6 and 2,6-diaminopurine   
 
 
4.4.6 18-crown-6/dicyandiamide (F) 
Crystallization of 18C6 and dicyandiamide affords a 1:1 supramolecular complex.  The 
co-crystal, F, as shown in Figure 12, is sustained by hydrogen bonds from the two amino 
group hydrogens from the dicyandiamide and two ether linkages from the crown.  
Distances range between 2.901-2.998Å.   Only one hydrogen atom from each amine 
group is involved in a hydrogen bond with the ether linkages.  The other hydrogen atoms 
are hydrogen bonded to other dicyandiamides, as in the 2,6-diaminopurine dimers of co-
crystal E.   Crown ether sheets are interlinked to each other by means of the 
dicyandiamide. 
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Figure 28.  The 1:1 adduct of 18C6 and dicyandiamide.   
 
4.4.7 18-crown-6/5-aminoisophthalic acid (G) 
Crystallization of 18C6 and 5-aminoisophthalic acid affords a 1:1 supramolecular 
complex.  The co-crystal, G, as shown in Figure 13, is sustained in a honeycomb network 
by carboxylic acid dimers between the 5-aminoisophthalic acids and between amino 
hydrogens from the 5-aminoisophthalic acid and the crown ether linkages.  Distances 
range between 2.545-2.748Å for the carboxylic acid dimer and 3.008-3.179 Å for the two 
amino hydrogens and two ether linkages.  Two zigzag 5-aminoisophthalic acid chains are 
H-bonded to each other through the amino-ether H-bonds, forming the honeycomb 
network.  Each crown ether is bonded to two amine groups of the 5-aminoisophthalic 
acid molecule, one above and one below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  The 1:1 adduct of 18C6 and 5-aminoisophthalic acid.   
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4.4.8 18-crown-6/tetrafluoroisophthalic acid/H2O (H) 
Crystallization of 18C6 and tetrafluoroisophthalic acid/H2O affords a 1:1 
supramolecular complex.  The co-crystal, H, as shown in Figure 14, is sustained by 
hydrogen bonds through a bridging water molecule.  The hydroxy group of the carboxylic 
acid is H-bonded to the oxygen in the water molecule and the distances range from 2.856-
2.891Å.  The water hydrogens are then H-bonded to two ether linkages at a distance of 
2.553 Å.  The tetrafluoroisophthalic acid bonded to the water molecule, which is then H-
bonded to the crown ether forming a screw.    
                                                                                                 
                      
Figure 30.  The 1:1 adduct of 18C6 and tetrafluoroisphthalic acid and water. 
 
4.5   Synthesis and Results 
 
4.5.1 Dibenzo-18-crown-6/4-nitroaniline 1:1 (A) 
 
 
Synthesis:  In a typical reaction, 30 mg (8.32x10-5 mol) Dibenzo-18-crown-6 and 17 mg 
(1.23x10-4 mol) 4-nitroaniline were dissolved in approximately 5 mL benzene.  Slow 
evaporation of the solvent for approximately a week yielded yellow 1:1 dibenzo-18-
crown-6/4-nitroaniline crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
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Crystal packing: The co-crystals are sustained by hydrogen bonds between the amine 
hydrogens and four ether linkages from the crown.  The two amino hydrogens involved 
in the H-bond are bifurcated.  Distances range between 3.050-3.115Å.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3459 cm-1 (N-H stretch, 1° amine, 4-
nitroaniline); 1310, 1248, 1217 cm-1 (C-O stretching, crown). 
 
Melt-temp: 120-122°C 
 
X-ray powder diffraction:  experimental done, calculated could not be done.   16.451, 
19.422, 20.340, 21.284, 21.422, 21.601, 21.749, 24.416. 
 
 
 
4.5.2 Dibenzo-18-crown-6/2-methyl-4-nitroaniline 1:1 (B) 
 
Synthesis:  In a typical reaction, 30 mg (8.32x10-5 mol) dibenzo-18-crown-6 and 14 mg 
(9.20x10-5 mol) of 2-methyl-4-nitroaniline were dissolved in approximately 5 mL 
benzene.  Slow evaporation of the solvent for approximately a week yielded yellow 1:1 
dibenzo-18-crown-6/2-methyl-4-nitroaniline crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: The co-crystals are sustained by hydrogen bonds between the amine 
hydrogens and three oxygens from the crown.  One of the amino hydrogens involved in 
the H-bond are bifurcated, the other is involved in a H-bond with just one oxygen.  The 
H-bond distances range between 2.484-3.465Å. 
    
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3369 cm-1(N-H stretch, 1° amine, 2-
methyl-4-nitroaniline); 1306, 1248cm-1 (C-O stretching, crown). 
 
Melt-temp: 137-139°C 
 
X-ray powder diffraction:   N/A 
 
 
4.5.3 Dibenzo-18-crown-6/Nicotinamide 1:1 Polymorph A (C) 
 
Synthesis:  In a typical reaction, 29 mg (8.05x10-5 mol) Dibenzo-18-crown-6 and 28 mg 
(1.53x10-4 mol) of nicotinamide were dissolved in approximately 4 mL THF.  Slow 
evaporation of the solvent for approximately a week yielded white 1:1 dibenzo-18-
crown-6/nicotinamide crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
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Crystal packing: The co-crystals are sustained by hydrogen bonds between one of the 
amino hydrogens and two ether linkages from the crown.  The amino hydrogen involved 
in the H-bond is bifurcated.  Distances range between 3.134-3.161Å.  The other hydrogen 
is at a distance of 3.330-3.362 Å away from two ether linkages as well.  This co-crystal 
has the nicotinamide molecule bonded through the outside of the crown ether bowl and 
will be referred to as Polymorph A.    
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3334 cm-1(N-H stretch, 1° amine, 
nicotinamide); 1326, 1252, 1227 cm-1 (C-O stretching, crown). 
 
Melt-temp:  N/A 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated): 13.239(13.092), 17.761(17.853), 19.679(19.482), 
22.006(22.134), 22.358(22.383), 24.142(24.170), 26.479(26.360), 30.239(30.256). 
 
 
4.5.4 Dibenzo-18-crown-6/nicotinamide 1:1  Polymorph B (D) 
 
Synthesis:  In a typical reaction, 290 mg (8.05x10-4 mol) Dibenzo-18-crown-6 and 123 
mg (1.01x10-3 mol) of nicotinamide were dissolved in approximately 24 mL THF.  Slow 
evaporation of the solvent for approximately a week yielded white 1:1 dibenzo-18-
crown-6/nicotinamide crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: The co-crystals are sustained by hydrogen bonds between the two amino 
hydrogens and two ether linkages from the crown.  Distances range between 2.995-
3.043Å.   This co-crystal has the nicotinamide molecule bonded through the inside of the 
crown ether bowl and will be referred to as Polymorph B.    
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3349 cm-1(N-H stretch, 1° amine, 
Nicotinamide); 1256, 1217 cm-1 (C-O stretching, crown). 
 
Melt-temp: 158-160°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated):  13.038(13.081), 17.736(17.842), 20.100(20.133), 
20.985(21.125), 22.225(22.201), 22.432(22.418), 23.716(23.751),     26.219(26.337),      
27.753(27.929),     30.052(30.191).  
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4.5.5 18-crown-6/2,6-diaminopurine 1:1 (E) 
 
Synthesis:  In a typical reaction, 31 mg (1.17x10-4 mol) 18-crown-6 and 30 mg (2x10-4 
mol) 2,6-diaminopurine were dissolved in approximately 4 mL ethanol.  Slow 
evaporation of the solvent for approximately a week yielded white 1:1 18-crown-6/2,6-
diaminopurine crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: The co-crystals are sustained by hydrogen bonds between the secondary 
amine hydrogen and ether linkages from the crown.  Two 2,6-diaminopurine molecules 
are involved in a dimer (NH2…N).  The secondary amine is then H-bonded to a crown 
oxygen. Distances range between 2.836-3.072Å.    
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3319 cm-1 (N-H stretch, 1° amine, 
2,6-diaminopurine); 3443 and 3478 cm-1  (secondary amine); 1391 cm-1 (C-O stretching, 
crown). 
 
Melt-temp: 223-227°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated): 9.382(9.459), 12.641(12.767), 18.441(18.347), 18.899(18.982), 
21.077(21.468), 22.960(22.640), 24.669(24.695),    24.801(24.877),      28.204(28.221). 
 
 
4.5.6 18-crown-6/dicyandiamide 1:1  (F) 
 
Synthesis:  In a typical reaction, 30 mg (1.13x10-4 mol) 18-crown-6 and 9 mg (1.07x10-4 
mol) of dicyandiamide were dissolved in a solvent system of 2mL of ethyl ether and 2mL 
of methanol.  Heated the solution, then slow evaporation of the solvent system for 
approximately a week.  Yielded colorless 1:1 dibenzo-18-crown-6/nicotinamide crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: The co-crystals are sustained by hydrogen bonds between the two amino 
hydrogens from the dicyandiamide and two ether linkages from the crown.  Distances 
range between 2.901-2.998Å   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3341, 3147 cm-1 (N-H stretch, 2° 
amine); 2878 cm-1 (2° amide); 1640 cm-1 (C=O),1096 cm-1 (C-O stretching). 
 
Melt-temp:  198-201 
 
X-ray Powder Diffraction:  in 2θ, simulated derived from the single the single crystal 
data; experimental (simulated):  9.680(9.837), 14.897(15.124), 17.239(17.181), 
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19.521(19.748), 20.403(20.389), 23.359(23.325), 23.519(23.802), 23.779(23.849), 
26.281(26.441), 27.567(27.519), 27.856(27.844), 29.143(29.483), 29.998(29.810). 
 
 
4.5.7 18-crown-6/5-aminoisophthalic acid 1:1 (G) 
 
Synthesis:  In a typical reaction, 30 mg (1.134x10-4 mol) of 18-crown-6 and 21 mg 
(1.23x10-4 mol) of 5-aminoisophthalic acid were dissolved separately in 2mL toluene and 
2mL THF respectively.  The two solvent mixtures were layered on top of one another 
according to their densities, with a 1mL layer of blank THF separating the two layers to 
make diffusion slower.  The reaction vial remained tightly capped in order to avoid 
solvent evaporation.  A few days later 1:1 crystals emerged. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: Crystallization of 18-C-6 and 5-aminoisophthalic acid affords a 1:1 
supramolecular complex sustained in a honeycomb network by carboxylic acid dimers 
and between amino hydrogens and the crown ether linkages.  Distances range between 
2.545-2.748Å for the carboxylic acid dimer and 3.008-3.179 Å for the two amino 
hydrogens and two ether linkages.   
 
Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  3437, 3356 cm-1 (N-H stretch, 2° 
amine); 2878 cm-1 (2° amide); 1342, 1261, 1110 cm-1 (C-O stretching). 
 
Melt-temp: 276-280°C 
 
X-ray powder diffraction:  in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated):  14.528(14.761), 18.144(18.407), 19.100(19.521), 
20.502(20.953), 22.558(22.317), 24.021(24.425), 24.898(25.098),     25.880(25.954). 
 
 
 
4.5.8 18-crown-6/tetrafluoroisophthalic acid 1:1 (H) 
 
Synthesis:  In a typical reaction, 30 mg (1.134x10-4 mol) of 18-crown-6 and 25 mg 
(1.05x10-4 mol) tetrafluoroisphthalic acid were dissolved in approximately 1 mL of 
methanol.  Slow evaporation of the solvent for approximately a month yielded yellow 1:1 
crystals. 
 
Crystal data:  (Bruker SMART-APEX CCD Diffractometer).  Appendix C 
 
Crystal packing: Crystallization of 18-C-6 and tetrafluoroisophthalic acid/H2O affords a 
1:1 supramolecular complex sustained by hydrogen bonds of OH groups and ether 
linkages through a bridging water molecule.  The HO…O distance is 2.553Å.   
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Infrared Spectroscopy: (Nicolet Avatar 320 FTIR).  N/A, not enough crystal sample and 
could not reproduce results.  
 
Melt-temp: N/A 
 
X-ray powder diffraction:  N/A 
 
4.6 Discussion 
Presented above were eight examples of the use of supramolecular synthesis to 
generate new compositions of matter that contains molecules of interest to materials 
scientists.  These results also indicate that hitherto inaccessible alignments of dipoles can 
be generated and that polymorphism in multiple component phases further adds to the 
structural diversity of such compounds.  Although all structures presented involved 
hydrogen bond donors (amines, carboxylic acids, etc), the crystal structure was not 
uniform from co-crystal to co-crystal.  Geometry, sterics, solvent systems, and synthons 
in the additives accounted for many differences when compared to the pure crystal 
structures of the pure crown ethers.  It is important to point out that not all available 
hydrogen atoms were involved, in the hydrogen bonding.  There are distance ranges 
(obtained from statistical data) that must be taken into account.  These supramolecular 
complexes show how ether linkages in pharmaceutical drugs can be exploited via crystal 
engineering.  This has increased the potential to control solid-state structures, changing 
their physical properties and leading to improved solubility and bioavailability. 
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Chapter 5 
Trimesic Acid 
5.1  Porous Materials 
   Trimesic acid (benzene-1,3,5-tricarboxylic acid, TMA) predictably generates 
honeycomb networks with interesting supramolecular properties because of its molecular 
symmetry and complementary hydrogen-bonding capabilities.26    
 
OHO
OO
OH OH  
Figure 31. Trimesic acid stick models.  The hydrogens have been omitted for clarity. 
 
 
Hydrogen-bonded supramolecular synthons represent a primary tool for crystal 
engineering.27   The rational design of host lattices using the principles of crystal 
engineering9,28,29 and self-assembly through supramolecular synthons has increased in the 
last few years.  Of particular interest are the efforts to create new clathrates or 
nanoporous materials, in which the target network is porous, contrary to Kitaigorodski’s 
principle of close crystal packing.30  Open framework structures of Trimesic acid can be 
designed via crystal engineering to build porous hydrogen bonded honeycomb networks.  
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The directional motif formed by the acid…acid dimer (Figure 1), along with the 
symmetric placement of acid groups around the benzene ring, derives the desired 
honeycomb framework with 14Å pores or cavities.31   These pores encapsulate aromatic 
guests.   
 
Figure 32. Acid…Acid Dimer motif representing a hydrogen-bonded supramolecular homosynthon.   
O
OH O
HO
 
 
 
Table 9.  Table shows the results of a CSD analysis of 1116 entries with the COOH…COOH synthons.   
 
0.064432.554-3.196Å 2.657Å 
σ Range Average 
 
 
 
 
 
    Porous materials are crystalline or amorphous solids that permit the inclusion of small 
molecules through holes in their structures.  Structural chemists and materials scientists 
have been interested in building these frameworks not only to understand their design 
principles, but also because of their diverse commercial applications such as chemical 
separation, asymmetric synthesis, catalysis, storage, etc.  Interpenetration of the host 
lattice is undesirable for porous networks because it fills space and usually produces 
global structural changes.29   
    Very few organic hydrogen bonded networks have been analyzed to date. A survey of 
the Cambridge Structural Database14 (CSD) showed the crystal structure of tetrakis(4-
ethynylphenyl)methane as the first example of a diamondoid packing motif generated by 
weak hydrogen bonding.  A three-dimensional network is formed by hydrogen bonds 
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between the alkynyl groups of four separate molecules, which meet to form the nodes of 
the network.  This network is absent of any guest molecules.32   
   Another example of an aromatic hydrogen bonded network is the orthogonal 
anthracene-bis(resorcinol) tetraol, a host structure that builds an extensive hydrogen-
bonded network resulting in a molecular sheet.  This sheet contains large supramolecular 
cavities, which incorporate two molecules of solvent guest.33   The crystal packing of this 
structure is comparable to the 3-connected honeycomb network coordination polymer, 
topologically equivalent to the 2-D brick wall.34 This organic network is held together by 
H-bonds between the OH groups of the host molecules creating cavities.  Each 
supramolecular cavity can bind a guest molecule (i.e. benzophenone) via hydrogen 
bonded OH groups of the host and the carbonyl group of the guest.32  
 
5.2  TMA Polymorphic Forms 
    Trimesic acid has been identified in four polymorphic forms, α35,β36,γ36 and δ37 
(Figure 2).  All of these polymorphs contain the carboxylic acid homosynthon, which 
generates the expected honeycomb network with an approximate 14Å diameter void.  
The α-form was developed by a solvent free host with non-planar two-dimensional 
interpenetrated networks with large rings created by six molecules of Trimesic acid.11  
The β-form is enantiotropically transformed from heating the α-form at high temperature 
(~543K).12  Since the β-form is a polycrystalline phase, no known crystal structure exists 
for the β polymorph.12  The γ-form is the flat triple catenated honeycomb network with 
inclusion of small guest molecules and it is less closely packed than the α-form.12  The δ-
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form possesses large channels which do not interpenetrate, but rather include guest 
molecules of bigger size.13    
 
 
1)                                              2)                                                          3) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  Schematic representations of TMA forms: 1) α-form; non-planar interpenetrated honeycombs, 
2)γ-form; planar triply interpenetrated honeycombs, and 3) δ-form; non-interpenetrated honeycombs.  
There is no known form of the β-form at room temperature. 
 
    
5.3  Strategy 
   Attempts to prepare the pure trimesic acid honeycomb network (with COOH dimer 
distances ranging from 2.609-2.657 Å) phase by breaking the interpenetration was carried 
out with different guest molecules, such as toluene, naphthalene, anthracene, acetic acid 
and biphenyl.  During this study, a new TMA honeycomb network truncated by acetic 
acid molecules was observed.  Additionally, this new form of TMA, ε-form, was 
observed when toluene and naphthalene are the aromatic guests held in the TMA 
honeycomb network cavities.  Having studied each of these phases structurally, we then 
studied the thermal stability of these crystals by Thermal Gravimetric Analysis (TGA) 
experiments since the honeycomb network remained in single crystal form even after 
guest removal. 
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Table 10. Trimesic Acid Supramolecular Complexes 
Trimesic Acid/Biphenyl A 
Trimesic acid/Anthracene B 
Trimesic acid/Acetic acid C 
Trimesic acid/Naphthalene D 
Trimesic acid/Toluene E 
 
 
           
CH3O
CH3 OH
  BIPHENYL                                ANTHRACENE
ACETIC ACID              NAPHTHALENE                  TOLUENE  
Figure 34.  Structures of the co-crystal formers used in the supramolecular complexes with TMA. 
 
 
5.4 Structures 
5.4.1 Trimesic acid/biphenyl (A) 
   Laboratory results similar to the TMA δ-form include the TMA honeycomb networks 
with biphenyl and anthracene as the aromatic guests occupying the cavities.  Crystals of 
TMA/biphenyl A were grown from CS2/AcOH/Ethanol (EtOH); crystallized in the 
monoclinic P21 noncentric space group and the asymmetric unit cell consists of four 
trimesic acid molecules and three biphenyl molecules.  The TMA/biphenyl structure 
differs from other TMA honeycomb networks because it does not include any solvent 
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molecules.  The honeycomb is held together by carboxylic acid dimers ranging in 
distance from 2.605 to 2.627 Å, falling within the acceptable range reported in Figure 1.   
 
 
 
Figure 35.  TMA honeycomb network with biphenyl guests in the cavity. 
5.4.2  Trimesic acid/anthracene (B) 
     Upon crystallization of TMA/anthracene B from CS2/AcOH/EtOH solvent system, 
crystals were obtained in the 2:1:1 ratio of TMA/anthracene/AcOH in the monoclinic 
P21/c space group.  The structure is not interpenetrated and each honeycomb framework 
(TMA dimer distance of 2.590-2.614 Å) encloses one anthracene molecule by creating C-
H…O (anthracene…TMA) interactions and an acetic acid dimer orthogonal to it (acetic 
acid dimer distance of 2.643 Å).  Again, the C-H…O hydrogen bond is due to guest 
inclusion rather than the stabilization of the guest by the C-H…O hydrogen bonds.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36.  TMA honeycomb with anthracene and acetic acid dimer guests in the cavity. 
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5.4.3 Trimesic acid/acetic acid (C) 
     Crystals of TMA/acetic acid (AcOH) C were obtained when trimesic acid was 
crystallized from CS2/AcOH/EtOH.  It crystallizes in the Pī space group with six 
molecules of trimesic acid and three molecules of acetic acid in the asymmetric unit.  Of 
the three acetic acid molecules, two produce the acetic acid dimer (Dimer distance of 
2.647Å) and the third one is used in constructing the truncated TMA honeycomb network 
(dimer distance of 2.717 Å).  Analysis of the packing of TMA/AcOH reveals that they 
are closely related to the γ-form, but differ by the incorporation of the acetic acid in the 
network.  The acetic acid forms the truncated honeycomb by terminating the normal two-
dimensional honeycomb framework.  It is unclear why the dimer between the acetic acid 
(strong acid) – trimesic acid (weak acid) COOH…COOH synthon is formed.  It may be 
rationalized that in order to include the guest, the void space must be created by 
terminating the two-dimensional honeycomb framework with acetic acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37.  Truncated acetic acid TMA honeycomb network. 
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      Results showing the new TMA polymorph with acetic acid truncated honeycomb 
networks, ε-form, were obtained with naphthalene and toluene as the guest molecules 
(Figure 6 and 7).     
 
5.4.4   Trimesic acid/Naphthalene (D) 
    Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of 
TMA/naphthalene/acetic acid.  Due to the smaller size of the guest, the framework is 
triply interpenetrated (as in TMA polymorphic forms α and γ) but differs from these 
forms because the acetic acid instead of creating dimers with itself, generates the 
acid…acid (distance of 2.624-2.704 Å) dimer with trimesic acid, truncating the TMA 
honeycomb network.  Trimesic acid forms an infinite two-dimensional honeycomb 
network (TMA dimer distance of 2.582-2.623 Å), which interpenetrates with three 
truncated honeycomb networks.  The naphthalene guest molecules are disordered, 
occupying the void created between the interpenetration rather than fitting into the 
honeycomb framework.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38.  TMA honeycomb networks with acetic acid truncated networks with naphthalene.    
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5.4.5 Trimesic acid/Toluene (E) 
 
     Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of TMA/toluene/acetic 
acid.  Due to the smaller size of toluene, the framework is triply interpenetrated (as in 
TMA polymorphic forms α and γ) but differs from these forms because the acetic acid 
instead of creating dimers with itself, generates the acid…acid (as in D) (TMA dimer 
distance of 2.605-2.632 Å, TMA-Acetic acid dimer distance of 2.6209-2.710 Å).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39.  TMA honeycomb networks with acetic acid truncated networks with toluene guests.    
 
5.5 Synthesis and Results 
5.5.1 Trimesic Acid/biphenyl (A) 
Synthesis:  In a typical reaction, 58 mg (2.76x10-4 mol) of TMA and 47 mg (3.05x10-4 
mol) of biphenyl were layered in 6 mL ethanol and 6 mL CS2, respectively.  A 4 mL 
layer of acetic acid separated the two layers.  Slow evaporation and in approximately two 
weeks crystals appeared. 
Crystal data: (Bruker SMART-APEX CCD Diffractometer).  Appendix D 
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Crystal Packing:  TMA honeycomb networks with biphenyl as the aromatic guests 
occupying the cavities.  The honeycomb is held together by carboxylic acid dimers 
ranging in distance from 2.605 to 2.627Å. 
Infrared Spectroscopy:  (Nicolet Avatar 320 FTIR).   Not much changes from pure TMA 
since the honeycomb network remained the same.  The peaks did shift slightly downfield.  
3127 cm-1 (-OH stretch), 1691 cm-1 (C=O stretch), 1261 cm-1 (C-O stretch). 
Melt-temp: 362-370ºC 
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated): 9.296(9.297), 12.240(12.112), 16.081(16.374), 17.243(17.480), 
22.206(22.330), 26.721(26.769), 33.499(33.370). 
 
5.5.2  Trimesic Acid/anthracene (B) 
 
Synthesis:  In a typical reaction, 20 mg (9.51x10-4 mol) of TMA and 17 mg (9.54x10-5 
mol) of anthracene were layered in 1 mL ethanol and 1 mL CS2, respectively.  A 1 mL 
layer of acetic acid separated the two layers.  Slow evaporation and in approximately two 
to three weeks crystals appeared. 
Crystal data: (Bruker SMART-APEX CCD Diffractometer).  Appendix D 
Crystal packing:  Crystallization of TMA with anthracene resulted in a structure that is 
not interpenetrated and each honeycomb framework (TMA dimer distance of 2.590-2.614 
Å) encloses one anthracene molecule by creating C-H…O (anthracene…TMA) 
interactions and an acetic acid dimer orthogonal to it (acetic acid dimer distance of 2.643 
Å). 
Infrared Spectroscopy:  (Nicolet Avatar 320 FTIR).  Not much changes from pure TMA 
since the honeycomb network remained the same.  The peaks did shift slightly downfield.  
3209 cm-1 (-OH stretch), 1698 cm-1 (C=O stretch), 1276 cm-1 (C-O stretch). 
 
Melt-temp: started melting 278ºC, decomposed before melting completely. 
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated): 11.035(11.056), 12.526(12.480), 13.010(13.070), 
14.198(14.121), 17.324(17.153), 22.979(22.905), 23.080(23.035), 25.119(25.111), 
26.300(26.314), 27.121(27.188), 30.011(30.002). 
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5.5.3 Trimesic Acid/acetic Acid (C) 
 
Synthesis:  In a typical reaction, 24 mg (1.14x10-4 mol) of TMA was dissolved in 1 mL 
of ethanol.  Separately, 4 drops of benzene were dissolved in 1 mL of CS2.   The two 
layers were put in a reaction vial with a 1 mL layer of acetic acid between then to slow 
down diffusion.  Slow evaporation and in approximately two weeks crystals appeared.  
The benzene served only as a template and did not appear in the crystal structure. 
Crystal data: (Bruker SMART-APEX CCD Diffractometer).  Appendix D 
Crystal Packing:  Crystallization of TMA and acetic acid results in a 1:1 supramolecular 
complex that is sustained by carboxylic acid H-bonds.  The acetic acid forms the 
truncated honeycomb by terminating the normal two-dimensional honeycomb 
framework.  Distances range between 2.647-2.717 Å. 
Infrared Spectroscopy:  (Nicolet Avatar 320 FTIR).  Not much changes from pure TMA 
since the honeycomb network remained the same.  The peaks did shift slightly downfield.  
3117 cm-1 (-OH stretch), 1684 cm-1 (C=O stretch), 1397 and 1275 cm-1 (C-O stretch). 
Melt-temp:  363-364ºC 
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated):  12.887(12.906), 19.962(19.669), 20.037(20.039), 
22.463(22.461), 24.442(368), 26.841(26.974), 29.183(29.173), 30.319(30.333), 
30.880(30.879), 33.475(33.478), 35.127(35.127), 36.158 (36.154), 37.638(37.674), 
39.562(39.561). 
 
5.5.4 Trimesic Acid/naphthalene (D) 
 
Synthesis:  In a typical reaction, 21 mg (9.99x10-5 mol) of TMA and 11 mg (8.58x10-5 
mol) of naphthalene were dissolved separately in 1 mL ethanol and 1 mL CS2, 
respectively.  A 1 mL layer of acetic acid separated the two layers.  Slow evaporation and 
in approximately two weeks crystals appeared. 
 
Crystal data: (Bruker SMART-APEX CCD Diffractometer).  Appendix D 
 
Crystal Packing: Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of 
TMA/naphthalene/acetic acid.  Due to the smaller size of the guest, the framework is 
triply interpenetrated (as in TMA polymorphic forms α and γ), but differs from these 
forms because acetic acid instead of creating dimers with itself, generates the acid…acid 
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dimer (distance of 2.624-2.704Å) with TMA, truncating the TMA honeycomb network. 
 
Infrared Spectroscopy:  (Nicolet Avatar 320 FTIR).  Not much changes from pure TMA 
since the honeycomb network remained the same.  The peaks did shift slightly downfield.  
3138 cm-1 (-OH stretch), 1684 cm-1 (C=O stretch), 1268 cm-1 (C-O stretch). 
 
Melt-temp:  360-363ºC 
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated):  11.858(11.473), 12.701(12.742), 16.457(16.469), 
22.960(22.900), 24.459(24.550), 26.658(26.656), 27.824(27.806), 30.897(30.877), 
35.265(35.260). 
 
5.5.5 Trimesic Acid/toluene (E) 
Synthesis:  In a typical reaction, 25 mg (1.19x10-4 mol) of TMA was dissolved separately 
in 1 mL ethanol and ~5 drops of toluene was dissolved in 1 mL CS2, respectively.  A 1 
mL layer of acetic acid separated the two layers.  Slow evaporation and in approximately 
two days crystals appeared. 
Crystal data: (Bruker SMART-APEX CCD Diffractometer).  Appendix D 
Crystal Packing: Crystallization from CS2/AcOH/EtOH resulted in a 6:1:1 ratio of 
TMA/toluene/acetic acid.  Due to the smaller size of the guest, the framework is triply 
interpenetrated, but differs from these forms because acetic acid instead of creating 
dimers with itself, generates the acid…acid dimer (distance of 2.6209-2.710Å) with TMA, 
truncating the TMA honeycomb network. 
Infrared Spectroscopy:  (Nicolet Avatar 320 FTIR).  Not much changes from pure TMA 
since the honeycomb network remained the same.  The peaks did shift slightly downfield.  
3127 cm-1 (-OH stretch), 1695 cm-1 (C=O stretch), 1397 and 1265 cm-1 (C-O stretch). 
Melt-temp: 366-367ºC 
X-ray powder diffraction: in 2θ, simulated derived from the single the single crystal data; 
experimental (simulated):  16.344(16.345), 20.080(20.205), 22.335(22.283), 
24.522(24.567), 25.487(25.508), 27.001(27.017), 28.061(28.055), 29.301(29.351), 
30.582(30.503), 30.841(30.822), 33.028(33.036),  36.099(36.096),  37.703(37.700),         
39.079(39.062). 
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 5.6 Discussion 
 
Is it really possible to maintain the crystallinity and pores present in the TMA 
honeycomb networks even in the absence of guests?  Thermal Gravimetric Analysis 
(TGA) experiments carried out with the ε-form crystal of TMA/toluene and the single 
crystal were performed.  TGA measures the weight change in materials as a function of 
time and temperature.  The measurement provides basic information about the thermal 
stability of a chemical and its composition (change in mass of a sample vs. 
temperature).38,39  The samples were heated to 180°C to ensure the removal of all guest 
molecules (a weight % loss of ~12% was evident in both TGA spectra).  Single crystal X-
ray data revealed that cell parameters before TGA and after guest removal by TGA 
remained the same, confirming retention of crystallinity and the hydrogen-bonded 
network. 
Table 11.  TMA/toluene crystal data before and after TGA analysis.   
 
 
Before 
TGA 
After 
TGA 
a (Å)  15.4991 15.2245 
b (Å)  16.2684 16.345 
c (Å)  16.4957 16.54 
α(°) 119.309 119.556 
β(°) 90.907 90.477 
γ (°) 117.171 116.276 
Volume (Å3)  N/A 3072.9 
Space grp P-1 P-1 
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 The large open honeycomb network of TMA is built by strong, yet, flexible 
supramolecular synthons (acid…acid) and by accommodating aromatic guests in the 
cavities.  These guest molecules inhibit the honeycomb networks from interpenetrating 
and assembling into a close packed conformation.  Removal of the guest can be 
accomplished while retaining the hydrogen bonded aromatic framework.  
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Chapter 6 
 
Conclusion 
 
 
   The concept of crystal engineering was first coined by Schmidt in the context of 
covalent synthesis in the solid state, i.e. topochemical reactions.2   However, recent 
development of this subject has expanded it into areas as diverse as supramolecular 
synthesis,3,4,9,40 crystal structure analysis and prediction41-45 and functional materials.46-48  
As previously stated, the concept of crystal engineering was originally introduced in the 
context of stereochemical control of photochemical reactions,2 but it has subsequently 
been shown to have wider implications for materials science. In the context of 
pharmaceuticals, there are important process and intellectual property implications 
related to control and reproducibility of composition and polymorphism.12,49  This work 
focused  upon how previously known supramolecular synthons could be exploited to 
rationally generate binary crystals with “engineered” compositions. The study chose 
pharmaceutical molecules as the target system since they contain a wide range of 
synthons and understanding of the crystal structure – physical property relationship is 
essential for the continued application of these essential chemicals toward improving the 
overall health of society.   
    Hydrogen bonded supramolecular synthons represent a prototypal tool for crystal 
engineering9 and can be categorized as follows: 1) self-complementary synthons, in 
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which a single molecule self-assembles to form a “homosupramolecular synthon”  (e.g. 
carboxylic acid dimer) or 2) two or more complementary components, thereby creating a 
multiple component or “heterosupramolecular synthon”  (e.g. the hetero-dimer formed by 
pyridines and carboxylic acids). 
Supramolecular synthetic approaches offer a number of attractive features: the ability 
to exploit readily available molecules or ions in novel ways; their inherent modularity 
affords compositional and structural diversity; the use of non-covalent interactions makes 
for facile synthesis.  In short, supramolecular synthesis offers a combinatorial type of 
approach to synthesis of new structures and can afford a wide range of structural diversity 
without the need to break and form covalent bonds.  The phenomenon of polymorphism 
in crystal engineering cannot be ignored.  Polymorphism is defined as the phenomenon 
where the same chemical substance exists in different crystalline forms or different 
crystalline patterns.11   This phenomenon is more common among molecules with flexible 
conformations capable of hydrogen bonding.6   Supramolecular synthons are the 
structural units within molecules, which can be formed and/or assembled by synthetic 
operations6.  The supramolecular synthons present in polymorphic forms may be intact 
from form to form, therefore it can be stated that the supramolecular equivalents of 
structural isomers are crystalline polymorphs.6   The criteria for assessing the existence of 
polymorphs are different unit cell parameters, crystal packing arrangements and physical 
properties.11 
Rationally generating organic binary crystals that contain pharmaceutical components 
by exploiting supramolecular chemistry concepts should further the development of other 
novel pharmaceutical phases. Indeed, the creation of model binary crystals provides 
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supramolecular insight that could lead to structures that have a pharmaceutical 
advantage50 over the pure phase pharmaceuticals. The necessary information to create 
and develop binary crystals should be stored already in the known pharmaceutical 
molecule. It should be intuitive that modular structures, e.g. binary crystals based upon 
more than one component, are often more diverse and controllable than single component 
phases. It is now evident that supramolecular chemistry, defined as chemistry beyond the 
molecule,4 and “supramolecular assemblies” are inherently linked to the concepts of 
crystal engineering. 
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Appendix A: Crystallographic Data for Nifedipine Structures 
 
   
 A B C 
Formula C18H21N3O7 C92H96N12O28 C27H26N4O6 
  
m.p. (°C) 136-138   148-153  137-139 
Mol. Wt. 391.38 1817.81 502.52 
Crystal System Triclinic Monoclinic Triclinic 
Space Group P-1 P2(1)n P-1 
a (Å) 7.8268(11) 7.9310(14) 7.6332(7) 
b (Å) 10.667(15)     12.4945(22) 9.8375(9) 
c  (Å) 11.8401(16) 22.2611(37) 16.6567(15) 
        
α (°)  70.065(3) 90  101.689(2)  
β (°) 76.766(3) 90.198(8) 93.132(2) 
        
γ (°) 80.56(3)   90  95.396(2) 
Volume (Å3) 900.7(2) 2205.93(4) 1215.92(19) 
       
calc density (mg/cm3) 1.443 1.373 1.373 
Solvent Formamide Methanol Methanol 
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Appendix B:  Crystallographic data for Phenytoin Structures 
 
  A B C 
Formula C80H22N4O2 C80H64N12O8 C27H22N4O2 
  
m.p. (°C) 234-239   225-227 254-257 
Mol. Wt. 347.37 440.48 434.49 
Crystal System Monoclinic Monoclinic Triclinic 
Space Group P21/c P21/c P-1 
a (Å) 16.6583(19) 8.0106(10) 8.620(14) 
b (Å) 8.8478(10)     26.2398(33) 9.929(14) 
c  (Å) 11.9546(14) 7.981(10) 13.29(2) 
        
α (°) 90  90  87.47(4) 
β (°) 96.618(2) 91.069(2) 84.03(3) 
        
γ (°) 90  90  86.13(3)  
Volume (Å3) 1750.2(3) 1677.4(4) 1128(3) 
       
calc density (mg/cm3)  1.318 1.308 1.28 
Solvent Ethanol/acetone 2,4-pentanedione 2,4-pentanedione
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Appendix C:  Crystallographic Data for Crown Ether Structures 
 
 
 
  A B C D E F G H 
Formula C58H66N6O18 C27H30N2O7 C26H30N2O7 C26H30N2O7 C51H87N18O18 C16H32N8O6 C60H60N2O20 C78H132O39F16
 
 m.p. (°C) 120-122 137-139 N/A 158-160 284-286 194-198 276-280 1997.84 
Mol. Wt. 1135.17 512.55 482.52 482.52 1240.206 432.5 1129.14 1997.84 
Crystal System Orthorhombic Monoclinic Monoclinic Orthorhombic Monoclinic Monoclinic Orthorhombic Monoclinic 
Space Group Fdd2 P21/n P21/c P212121 P21/c I2/a C2 P21/n 
a (Å) 42.769(3) 13.5993(14) 8.4015(13) 7.9634(28) 15.452(2) 7.6625(48) 8.8849(28)
b (Å) 52.193(3) 9.3950(10) 9.8132(16) 13.650(2) 13.8565(51) 8.1949(10) 16.929(99) 20.584(71)
c  (Å) 11.1128(7) 20.885(2) 17.266(3) 20.705(3) 12.6933(40) 18.215(3) 11.713(73) 14.102(42)
β (º) 90 103.445(2) 111.615(3) 90 94.661(12) 99.445(2) 90 105.952(8)
Volume (Å3) 24806(3) 2595.2(5) 2513.3(7) 2374.5(7) 1396.008 2275.2(6) 1579.4(16) 2479.67(4)
calc density 
mg/cm3) 1.216 1.312 1.275 1.35 1.475 1.263 1.317 1.338 
Ether/ 
Solvent Benzene Benzene THF THF Ethanol Methanol 
Toluene/ 
THF Methanol 
15.956(3)
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Appendix D: Crystallographic Data for Trimesic Acid Structures. 
 
 
  A B C D E 
Formula C72H54O24 C34H24O24 C120H96O84 C133H98O42 C126H112O48 
  
m.p. (°C)  362-370 decomposed   363-364 360-363  366-367  
Mol. Wt. 186.16 656.53 2881.97 2368.11 2418.18 
Crystal System Monoclinic Monoclinic Triclinic Triclinic Triclinic 
Space Group P21 P-1 P-1 P-1 P-1 
a (Å) 9.9791(10) 10.4027(8) 15.4543(14) 15.4148(21) 15.4991(34) 
b (Å) 28.424(3)     28.560(2) 16.3494(15) 16.3203(22) 16.2684(35) 
c  (Å) 11.0164(11) 10.4430(8) 16.5130(14) 16.3669(23) 16.4957(36) 
            
α (°) 90  90  119.409(2)    119.516(2) 119.309(6)  
β (°) 104.243(3) 105.226(2) 90.449(2) 90.349(3) 90.907(9) 
            
γ (°)  90  90 117.481(1) 117.499(2)  119.171(5)  
Volume (Å3) 3028.7(5) 2993.7(4) 3072.21(2) 3029.29(7) 3069.21(5) 
           
calc density (mg/cm3) 1.429 1.312 1.558 1.298 1.308 
Solvent CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH CS2/AcOH/EtOH
 
 
 
 
 
 
